TY - JOUR
T1 - When designing vaccines, consider the starting material
T2 - the human B cell repertoire
AU - Havenar-Daughton, Colin
AU - Abbott, Robert K.
AU - Schief, William R.
AU - Crotty, Shane
N1 - Funding Information:
We thank Daniel Kaufmann for helpful conversations regarding human LN size and composition. This work was supported by the National Institute of Health, NIAID [grant numbers UM1 AI100663 (CHAVI-ID. SC, CHD, WRS) and R01 AI124796 (SC)], as well as a Bill & Melinda Gates Foundation CAVD grant (WRS). The NIH Office of the Director supported purchase of a BD FACSAria II [grant number S10RR027366] and an Illumina HiSeq 2500 [grant number S10OD016262] that provided data supporting this work. RKA was funded by the La Jolla Institute T32 training grant [grant number AI125179].
Publisher Copyright:
© 2018 The Authors
PY - 2018/8
Y1 - 2018/8
N2 - Most viral vaccines provide protection from infection through the generation of neutralizing antibodies (nAbs). The repertoire of B cells responding to immunization is the starting material from which nAbs eventually arise. Immunization strategies are increasingly targeting precise B cell specificities to mimic nAbs generated during natural infection, in an effort to maximize the potency of the vaccine-elicited Ab response. An understanding of the human B cell specificities capable of immunogen recognition can aid in immunogen design and inform decision-making for clinical advancement. Here, we review what is known about antigen-specific and epitope-specific naive B cell repertoires in humans and mice, and we consider the challenges for identifying and analyzing antigen-specific naive B cell repertoires. Finally, we provide a framework for further exploration, interpretation, utilization of the B cell repertoire to facilitate vaccine discovery.
AB - Most viral vaccines provide protection from infection through the generation of neutralizing antibodies (nAbs). The repertoire of B cells responding to immunization is the starting material from which nAbs eventually arise. Immunization strategies are increasingly targeting precise B cell specificities to mimic nAbs generated during natural infection, in an effort to maximize the potency of the vaccine-elicited Ab response. An understanding of the human B cell specificities capable of immunogen recognition can aid in immunogen design and inform decision-making for clinical advancement. Here, we review what is known about antigen-specific and epitope-specific naive B cell repertoires in humans and mice, and we consider the challenges for identifying and analyzing antigen-specific naive B cell repertoires. Finally, we provide a framework for further exploration, interpretation, utilization of the B cell repertoire to facilitate vaccine discovery.
UR - http://www.scopus.com/inward/record.url?scp=85052742637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052742637&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.08.002
DO - 10.1016/j.coi.2018.08.002
M3 - Review article
C2 - 30190230
AN - SCOPUS:85052742637
SN - 0952-7915
VL - 53
SP - 209
EP - 216
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -